Clinical Trials for Mesothelioma Patients—A Study of Decitabine and FR901228

Read about a current clinical trial about the use of Decitabine and FR901228 for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Decitabine and FR901228 in Treating Patients with Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases

Rationale:
Drugs used in chemotherapy, such as decitabine and FR901228, use different ways to stop tumor cells from dividing so they stop growing or die. Using more than one drug may kill more tumor cells.

Purpose:
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with unresectable advanced lung cancer, esophageal cancer, pleural mesothelioma, or lung metastases.

Phase, Condition and Intervention:
Phase I; Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer;
Drug: celecoxib, Drug: decitabine, Drug: romidepsin

Study Type and Design:
Interventional Treatment

Official Title:
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects With Pulmonary and Pleural Malignancies

Estimated Enrollment: 40

Study Start Date: May 2002
Estimated Primary Completion Date: July 2003 (Final data collection date for primary outcome measure)

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.